Guangzhou JOYO Pharma Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO40%
Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Guangzhou JOYO Pharma Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| JYP0061 15 mg NCT06158490 |
P2 | Enrolling by invitation | Moderate-to-severe Atopic Dermatitis | 120 | 2026-02-10 (+12 mo) |
| JYP0061 NCT06697535 |
P2 | Recruiting | Neuromyelitis Optica Spectrum Disorders | 35 | 2026-02-28 |
| STAR NCT06895031 |
P2 | Recruiting | Solid Tumor; Pancreatic Ductal Adenocarcinoma (PDAC) | 210 | 2026-03-30 |
| SC1011 NCT06125327 |
P2/3 | Recruiting | Idiopathic Pulmonary Fibrosis | 210 | 2026-12-31 (+12 mo) |
| JYP0066 4% topical cream NCT07843290 |
P2 | Not yet recruiting | Atopic Dermatitis (AD) | 160 | 2027-08-30 |
| Pemetrexed injection NCT07154368 |
P3 | Not yet recruiting | Non Small Cell Lung Cancer | 207 | 2027-10-31 |
| JYP0322 Tablets NCT07816380 |
P3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 216 | 2028-12-30 |